NT5E and neoplasm: AB680, a reversible and selective inhibitor of CD73, is currently is presently undergoing evaluation in early‐stage clinical trials owing to its remarkablely extended half‐lives and favorable tolerability.[14, 15] In immune‐competent mice with KPC and Panc02 subcutaneously implanted tumor models, tumor volume and weight of AB680‐treated allografts were significantly reduced compared to controls (Figure 3A–D; Figure S3A–D, Supporting Information).